{"id":"adjuvanted-pbs","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Systemic reactions (fever, myalgia, fatigue)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PBS (Peptide-Based Seasonal) vaccine uses a multi-epitope approach targeting conserved regions of influenza proteins, combined with an adjuvant to enhance immunogenicity. The adjuvant amplifies the body's innate immune response, enabling stronger and broader T-cell and B-cell activation against multiple influenza subtypes. This approach aims to provide improved cross-strain protection compared to conventional inactivated vaccines.","oneSentence":"Adjuvanted PBS is a polyepitope peptide-based vaccine that stimulates broad immune responses against multiple influenza strains by combining conserved viral peptides with an adjuvant.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:19:41.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention"}]},"trialDetails":[{"nctId":"NCT06842173","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2025-09-01","conditions":"Avian Influenza A Virus","enrollment":700},{"nctId":"NCT06768697","phase":"EARLY_PHASE1","title":"Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2024-12-30","conditions":"COVID - 19","enrollment":60},{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034},{"nctId":"NCT00877448","phase":"PHASE1, PHASE2","title":"A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2009-06","conditions":"Healthy","enrollment":63},{"nctId":"NCT03275389","phase":"PHASE1","title":"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-08","conditions":"Influenza, Human","enrollment":470},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT03330899","phase":"PHASE1","title":"Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2018-09-24","conditions":"Influenza, H7N9 Influenza","enrollment":432},{"nctId":"NCT03318315","phase":"PHASE2","title":"Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-20","conditions":"Avian Influenza, Influenza, Influenza Immunisation","enrollment":149},{"nctId":"NCT03180801","phase":"PHASE2","title":"Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2016-08-18","conditions":"Influenza","enrollment":153},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT02415842","phase":"","title":"A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-26","conditions":"Immunologic Tests","enrollment":414},{"nctId":"NCT03425149","phase":"PHASE1","title":"Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2018-02-24","conditions":"Zika Virus, Zika Virus Infection","enrollment":67},{"nctId":"NCT00719043","phase":"PHASE2","title":"Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-11","conditions":"Influenza","enrollment":841},{"nctId":"NCT01556945","phase":"PHASE1, PHASE2","title":"Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2001-04","conditions":"Malaria, Falciparum","enrollment":72},{"nctId":"NCT01623232","phase":"PHASE1, PHASE2","title":"MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2012-10","conditions":"Influenza Vaccines, Aged","enrollment":""},{"nctId":"NCT01146119","phase":"PHASE2","title":"Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2010-07","conditions":"Influenza","enrollment":200},{"nctId":"NCT01010737","phase":"PHASE1, PHASE2","title":"A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2009-09","conditions":"Influenza","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo"],"phase":"phase_2","status":"active","brandName":"Adjuvanted PBS","genericName":"Adjuvanted PBS","companyName":"BiondVax Pharmaceuticals ltd.","companyId":"biondvax-pharmaceuticals-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adjuvanted PBS is a polyepitope peptide-based vaccine that stimulates broad immune responses against multiple influenza strains by combining conserved viral peptides with an adjuvant. Used for Seasonal influenza prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}